New Pharmatech CEO expects larger external sales – but this won't weaken relationship with Novo Nordisk

Ulla Grove Krogsgaard Thomsen is the new CEO for Novo Nordisk Pharmatech, and according to the CEO, external sales will take up more space in the future. At the same time, she establishes that this will not weaken the firm's relationship with parent company Novo Nordisk.
New CEO for Novo Nordisk Pharmatech Ulla Grove Krogsgaard Thomsen. | Photo: Novo Nordisk Pharmatech / PR
New CEO for Novo Nordisk Pharmatech Ulla Grove Krogsgaard Thomsen. | Photo: Novo Nordisk Pharmatech / PR
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY NIELSINE NIELSEN

From April 1, Ulla Grove Krogsgaard Thomsen will lead Novo Nordisk Pharmatech, and the future CEO expects sales for the company's external clients will take up an even larger portion during her management in future years, she tells MedWatch.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading